Skip to Main Content

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second quarter:

Alnylam Pharmaceuticals has guided to a mid-year readout of its APOLLO-B Phase 3 study, which is attempting to expand the use of its approved RNA-interference medicine Onpattro to encompass a significantly larger group of patients with transthyretin amyloidosis cardiomyopathy, or ATTR-CM, a progressive heart disease caused by the buildup of a toxic protein. Currently, Onpatrro is approved to treat patients with a form of transthyretin amyloidosis that mostly affects nerves and other organs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment